港股異動 | 四環醫藥(0460.HK)漲4.7% 聯營公司獲得新增投資方增資
格隆匯8月20日丨四環醫藥(0460.HK)現報0.88港元,漲幅4.76%,最新總市值83.3億港元。公司19日公告稱,廣東冠潤股權投資合夥企業(有限合夥)和南靖惠及股權投資合夥企業(有限合夥)對集團聯營公司北京鋭業進行增資。完成後,北京鋭業的整體估值為人民幣29億元,集團持股比例為40.966%,兩位投資方共佔6.896%。北京鋭業目前具有非PVC粉液雙室袋即配型輸液領先技術。已經獲得該劑型頭孢他啶、頭孢呋辛、頭孢地嗪多個品種和規格的生產批件。此次增資,體現了投資方對北京鋭業雙室袋業務的認可,以及對頭孢他啶、頭孢呋辛、頭孢地嗪三個抗生素產品廣闊市場前景的期待。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.